Mechanisms of resistance and failure of treatment with maraviroc;Mecanismos de resistencia y fracaso al tratamiento con maraviroc

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 11, 2008, Pages 28-33

  Delgado, Rafael ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

CCR5; CXCR4; Maraviroc; Resistance; Tropism

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; GLYCOPROTEIN GP 120; LAMIVUDINE; MARAVIROC; ZIDOVUDINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; CYCLOHEXANE DERIVATIVE; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HIV ENVELOPE PROTEIN GP120 (305 321); HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; TRIAZOLE DERIVATIVE; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MUTATION; NONHUMAN; PHENOTYPE; PLANT GROWTH; TREATMENT FAILURE; VIRUS ENTRY; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENVELOPE GENE; GENETIC SELECTION; GENETICS; MEMBRANE FUSION; MOLECULAR GENETICS; MULTICENTER STUDY; PHYSIOLOGY; REVIEW; STATISTICS; VIRUS ATTACHMENT;

AMINO ACID SEQUENCE; CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, ENV; HIV; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; MULTICENTER STUDIES AS TOPIC; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SELECTION (GENETICS); TREATMENT FAILURE; TRIAZOLES; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 65449171121     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76561-3     Document Type: Article

References (37)

1. G. Fatkenheuer, A.L. Pozniak, M.A. Johnson, A. Plettenberg, S. Staszewski, and A.I. Hoepelman Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 Nat Med 11 2005 1170 1172 (Pubitemid 43093663)
2. M. Westby, C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, and M. Stockdale Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry J Virol 81 2007 2359 2371 (Pubitemid 46303353)
3. P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, and M. Macartney Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob Agents Chemother 49 2005 4721 4732 (Pubitemid 41552605)
4. K. Maeda, D. Das, H. Ogata-Aoki, H. Nakata, T. Miyakawa, and Y. Tojo Structural and molecular interactions of CCR5 inhibitors with CCR5 J Biol Chem 281 2006 12688 12698 (Pubitemid 43855359)
5. D.S. Dimitrov Cell biology of virus entry Cell 101 2000 697 702
6. P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, and M. Macartney Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob Agents Chemother 49 2005 4721 4732 (Pubitemid 41552605)
7. A.G. Dalgleish, P.C.L. Beverley, P.R. Clapham, D.H. Crawford, M.F. Greaves, and R.A. Weiss The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus Nature 312 1984 763 768
8. E. Oberlin, A. Amara, F. Bachelerie, C. Bessia, J.L. Virelizier, and F. Arenzana-Seisdedos The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 Nature 382 1996 833 835 (Pubitemid 26299571)
9. H. Deng, R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, and M. Burkhart Identification of a major co-receptor for primary isolates of HIV-1 Nature 381 1996 661 666 (Pubitemid 26197679)
10. E.M. Long, S.M. Rainwater, L. Lavreys, K. Mandaliya, and J. Overbaugh HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus AIDS Res Hum Retroviruses 18 2002 567 576 (Pubitemid 34579536)
11. A. Bjorndal, H. Deng, M. Jansson, J.R. Fiore, C. Colognesi, and A. Karlsson Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype J Virol 71 1997 7478 7487 (Pubitemid 27391688)
12. Z.L. Brumme, J. Goodrich, H.B. Mayer, C.J. Brumme, B.M. Henrick, and B. Wynhoven Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals J Infect Dis 192 2005 466 474 (Pubitemid 41023125)
13. B.J. Doranz, J. Rucker, Y. Yi, R.J. Smyth, M. Samson, and S.C. Peiper A dualtropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors Cell 85 1996 1149 1158 (Pubitemid 26235280)
14. R.L. Willey, T.S. Theodore, and M.A. Martin Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope J Virol 68 1994 4409 4419
15. M.A. Jensen, and A.B. 't Wout Predicting HIV-1 coreceptor usage with sequence analysis AIDS Rev 5 2003 104 112 (Pubitemid 36873899)
16. W. Huang, J. Toma, S. Fransen, E. Stawiski, J.D. Reeves, J.M. Whitcomb, et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein J Virol 2008 Online publication. PMID: 18353956
17. L. Waters, S. Mandalia, P. Randell, A. Wildfire, B. Gazzard, and G. Moyle The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen Clin Infect Dis 46 2008 1617 1623 (Pubitemid 351706746)
18. C. Pastore, A. Ramos, and D.E. Mosier Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching J Virol 78 2004 7565 7574 (Pubitemid 38915903)
19. Z. Chen, A. Gettie, D.D. Ho, and P.A. Marx Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac Virology 246 1998 113 124 (Pubitemid 28384065)
20. T. Cilliers, J. Nhlapo, M. Coetzer, D. Orlovic, T. Ketas, and W.C. Olson The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C J Virol 77 2003 4449 4456 (Pubitemid 36350986)
21. L. Morris, T. Cilliers, H. Bredell, M. Phoswa, and D.J. Martin CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis AIDS Res Hum Retroviruses 17 2001 697 701 (Pubitemid 32692408)
22. J. Bhattacharya, P.J. Peters, and P.R. Clapham CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo AIDS 17 Suppl 4 2003 S35 S43
23. D. Cecilia, C. Kleeberger, A. Muñoz, J.V. Giorgi, and S. Zolla-Pazner A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects J Infect Dis 179 1999 1365 1374 (Pubitemid 29246584)
24. Westby M. In vitro and in vivo tropism and resistance evaluation; 2007. Disponible en: www.fda.gov/ohrms/dockets/ac/07/slides/2007-4283s1-01-04-Pfizer- Westby.pdf
25. A.J. Low, W. Dong, D. Chan, T. Sing, R. Swanstrom, and M. Jensen Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates AIDS 21 2007 F17 F24 (Pubitemid 47329758)
26. J.M. Whitcomb, W. Huang, S. Fransen, K. Limoli, J. Toma, and T. Wrin Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism Antimicrob Agents Chemother 51 2007 566 575 (Pubitemid 46185274)
27. M. Margulies, M. Egholm, W.E. Altman, S. Attiya, J.S. Bader, and L.A. Bemben Genome sequencing in microfabricated high-density picolitre reactors Nature 437 2005 376 380 (Pubitemid 41613494)
28. M. Lewis, I. James, M. Braverman, B. Desany, T. Jarvie, M. Penny, et al. Evaluation of an ultra-deep sequencing method to identify minority sequence variants in the HIV-1 env gene from clinical samples 2007 14th CROI Los Angeles February 25-28
29. J. Reeves, D. Han, T. Wilkin, T. Wrin, D. Kuritzkez, C. Petropoulos, et al. An enhanced version of the trofile HIV co-receptor tropism assay predicts emergence of CXCR4 use in ACTG5211 vicriviroc trial samples 2008 15th CROI Boston February 3-6
30. P. Hunt, S. Deeks, W. Huang, E. Coakley, D. Han, C. Petropoulos, et al. Detection of viral co-receptor tropism changes with a high-sensitivity phenotypic assay among HIV-infected patients with drug-resistant viremia 2008 15th CROI Boston February 3-6
31. M. Westby, M. Lewis, J. Whitcomb, M. Youle, A.L. Pozniak, I.T. James, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir J Virol 80 2006 4909 4920
32. A. Trkola, S.E. Kuhmann, J.M. Strizki, E. Maxwell, T. Ketas, and T. Morgan HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use Proc Natl Acad Sci U S A 99 2002 395 400 (Pubitemid 34060372)
33. A.J. Marozsan, S.E. Kuhmann, T. Morgan, C. Herrera, E. Rivera-Troche, and S. Xu Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCHD) Virology 338 2005 182 199 (Pubitemid 40835936)
34. M. Lewis, J. Mori, P. Simpson, J. Whitcomb, X. Li, D. Roberston, et al. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials 2008 15th CROI Boston February 3-6
35. J. Mori, M. Lewis, and P. Simpson Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2 (24 week analysis) 6th European HIV Drug Resistance Workshop Buadapest, March 26-28 2008
36. K. Maeda, H. Nakata, Y. Koh, T. Miyakawa, H. Ogata, and Y. Takaoka Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/ CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro J Virol 78 2004 8654 8662 (Pubitemid 39025131)
37. J. Heera, M. Saag, P. Ive, J. Whitcomb, M. Lewis, L. McFadyen, et al. Virological correlates associated with treatment failure at week 48 in the phase 3 study of maraviroc in treatment-naive patients 2008 15th CROI Boston February 3-6